Aurora Cannabis Dominates 30% Of Canada's Medical Marijuana Exports: Will Its Bold International Expansion Pay Off?
Aurora Cannabis Dominates 30% Of Canada's Medical Marijuana Exports: Will Its Bold International Expansion Pay Off?
Aurora Cannabis (NASDAQ:ACB) saw its international sales for the first half of 2024 reach C$39.3 million ($28.9 million), reflecting a 31% year-over-year increase. This growth includes the full acquisition of MedReleaf Australia in February 2024, which contributed significantly to the sales boost. A Wednesday report by Pablo Zuanic of Zuanic & Associates provides a detailed analysis of the company's recent activities and financial standing.
极光大麻（纳斯达克：ACB）在2024年上半年的国际销售额达到了3930万加元（2890万美元），同比增长31%。这一增长包括了2024年2月对MedReleaf Australia的全面收购，这对销售增长起到了重大贡献。Pablo Zuanic of Zuanic & Associates在周三的一份报告中对该公司的最近活动和财务状况进行了详细分析。
International Sales And Market Position
国际销售和市场地位
Aurora remains a leader in the export of Canadian medical marijuana (MMJ), accounting for more than 30% of Canada's MMJ exports.
极光大麻仍然是加拿大医用大麻（MMJ）出口的领导者，占加拿大MMJ出口的30%以上。
Key markets include Australia, Germany, Israel, Czechia and Portugal, with notable growth in the Czech and Portuguese markets.
主要市场包括澳大利亚、德国、以色列、捷克和葡萄牙，捷克和葡萄牙市场增长明显。
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
免费订阅我们的新闻简报以获得Benzinga对大麻行业和市场的独家分析和头条新闻。如果你对这个行业很认真，不能错过。
Profit Margins And Cash Flow Trends
利润率和现金流趋势
The company reported encouraging profit margin trends, with adjusted cash gross margins for its global cannabis business reaching 69% in the June quarter, up from 66% in March and 61% a year ago.
该公司报告了令人鼓舞的利润率趋势，全球大麻业务的调整后现金毛利润在6月季度达到了69%，高于3月的66%和一年前的61%。
Despite this, recurring cash operating expenses in Q2 2024 were slightly higher than adjusted cash gross profits, leading to a 102% ratio.
尽管如此，在2024年第二季度，经常性现金运营费用略高于调整后现金毛利润，导致比率达到了102%。
Still, this represents an improvement compared to the previous fiscal year. Aurora's net cash position improved to C$63 million, with positive operating cash flows of C$8.4 million for the quarter.
然而，与上一个财年相比，这是一个改善。极光的净现金状况改善到C$6300万，并且本季度的正营业现金流量为C$840万。
Valuation And Strategic Outlook
估值和战略展望
Aurora Cannabis is currently valued at C$516 million, with an enterprise value of C$543 million. The company trades at 1.6 times its current sales run rate, significantly below the multiples seen by competitors like Tilray (NASDAQ:TLRY) and Canopy Growth (NASDAQ:CGC). Zuanic suggests that while Aurora's financial and operational trends are showing signs of improvement, the company's valuation remains relatively attractive compared to its peers.
极光大麻目前估值为C$51600万，企业价值为C$54300万。该公司的交易价格目前是其当前销售额的1.6倍，明显低于竞争对手Tilray（纳斯达克代码：TLRY）和Canopy Growth（纳斯达克代码：CGC）的倍数。Zuanic建议，尽管极光的财务和运营趋势正在显示改善迹象，但该公司的估值相对于同行公司仍然相对吸引。
Cover image made with AI
封面图片由人工智能制作